Novo commits $200 million to the World Diabetes Foundation
NVO•Novo Nordisk will commit $200 million to the World Diabetes Foundation over 10 years starting in 2027, supporting diabetes prevention and care in low- and middle-income countries.
1. Ten-year commitment
Novo Nordisk said the commitment will run through 2036 and give the World Diabetes Foundation greater certainty to plan long term, build on partnerships and scale regional and global responses to diabetes.
2. Diabetes drug competition
The company is looking to recover ground lost to U.S. rival Eli Lilly in the diabetes and obesity drug race, with Ozempic and Wegovy leading its charge. Earlier this month, Novo raised its 2026 outlook for the third time this year after quarterly Wegovy pill sales for weight loss beat forecasts.
